Then they designed CAR-T cells targeting c-Met and evaluated the safety and feasibility of c-Met-CAR-T cells for the treatment of metastatic breast cancer in a phase 0 clinical trial, and found extensive tumor necrosis at the injection site, tumor cell debris, and good tolerability [201]. This evidence concerns the gene MET and neoplasm.